AR070540A1 - Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer. - Google Patents

Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer.

Info

Publication number
AR070540A1
AR070540A1 ARP090100694A ARP090100694A AR070540A1 AR 070540 A1 AR070540 A1 AR 070540A1 AR P090100694 A ARP090100694 A AR P090100694A AR P090100694 A ARP090100694 A AR P090100694A AR 070540 A1 AR070540 A1 AR 070540A1
Authority
AR
Argentina
Prior art keywords
het
alq
hal
indicates
nhet
Prior art date
Application number
ARP090100694A
Other languages
English (en)
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of AR070540A1 publication Critical patent/AR070540A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos derivados de benzonaftiridinilo y análogos de los mismos, y procesos para preparar los mismos. Los compuestos son utiles en el tratamiento de enfermedades sensibles a la inhibicion, regulacion o modulacion de la transduccion de senales de cinasas. Reivindicacion 1: Un compuesto de acuerdo con la formula (1) en donde W se selecciona de Hal, Ar-alq, Het-alq, O, OH, SH, S(O)mZ, S(O)mAr, S(O)mHet, Z, OZ, OAr, OHet, OAlq o NRR'; Q es N o NH para satisfacer la valencia adecuada X se selecciona de N o [N+-O-]; ------- indica un enlace sencillo o doble; R1, R2, R3, R4, R5 y R6 se seleccionan independientemente de hidrogeno, Hal, Z, OZ, OAr, OHet, OH, NRR', Ar, Ar-alq, Het, Het-alq, S(O)mZ, S(O)mAr, S(O)mHet, C(O)mOR, NRC(O)mR', NRSO2R', NRC(O)mNR', (CH2)nOZ o C(O)NRR'; R y R' se seleccionan independientemente de hidrogeno, Z, Ar, Ar-alq, Het, Het-alq, OZ, OAr, S(O)mZ, S(O)mAr o S(O)mHet; Z indica alquilo ramificado o no ramificado C1-10, en la cual 1-7 átomos de H se pueden reemplazar por F, Cl y/o Br, y/o en la cual uno o dos grupos CH2 no adyacentes se pueden reemplazar por grupos O, N, NH, S, SO, SO2, y/o CH=CH, o alquilo cíclico C3-7; Ar indica fenilo, naftilo o bifenilo, cada uno de los cuales es no sustituido o mono-, di- o trisustituido por Hal, Z, OR, N(R)2, SR, NO2, CN, COOR, CON(R)2, NRCOZ, NRSO2Z, SO2N(R)2, S(O)mZ, CO-Het, Het, O[C(R)2]nN(R), O[C(R)2]nHet, NHCOOZ, NHCON(R)2, NHCOO[C(R)2]nN(R)2, NHCOO[C(R)2]pHet, NHCONH[C(R)2]nN(R)2, NHCONH[C(R)2]pHet, OCONH[C(R)2]nN(R)2, OCONH[C(R)2]nHet, CHO y/o COZ; Hal indica Cl, Br, I o F; Het indica independientemente un heterociclo mono-, bi- o tricíclico saturado, no saturado o aromático que tiene 1 a 4 átomos de N, O y/o S; que puede ser no sustituido o mono-, di- o trisustituido por Hal, Z, OR, (CH2)pN( R)2, SR, NO2, CN, COOR, CON(R)2, O[C(R)2]nN(R), O[C(R)2]nHet1, NHCOOZ, NHCON(R)2, NHCOO[C(R)2]nN(R)2, NHCOO[C(R)2]nHet, NHCONH[C(R)2]nN(R)2, NHCONH[C(R)2]nHet, OCONH[C(R)2]nN(R)2, OCONH[C(R)2]nHet, NRCOZ, NRSO2Z, SO2N(R)2, S(O)mZ, CO-Het, CHO, COZ, =S, =NH, =NZ, oxi (-O-) y/o =O (oxígeno de carbonilo); alq indica alquileno ramificado o no ramificado C1-10, en el cual 1-7 átomos de H se pueden reemplazar por F, Cl, y/o Br, y/o en el cual uno o dos grupos CH2 no adyacentes se pueden reemplazar por grupos O, S, SO, SO2, NH, NZ, CH=CH y/o C:::C, y que se pueden sustituir por Hal, OR, SR, Ar y/o =O; m es 0, 1 o 2; n es 0, 1, 2, 3, 4, 5 o 6; p es 0, 1, 2, 3 o 4, y en donde al menos uno de R1 a R6 no es H, y un profármaco, derivado, solvato, sal, tautomero y estereoisomero farmacéuticamente aceptable del mismo, incluyendo mezclas de los mismos en todas las proporciones.
ARP090100694A 2008-02-28 2009-02-27 Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer. AR070540A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6749208P 2008-02-28 2008-02-28

Publications (1)

Publication Number Publication Date
AR070540A1 true AR070540A1 (es) 2010-04-14

Family

ID=40622992

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100694A AR070540A1 (es) 2008-02-28 2009-02-27 Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer.

Country Status (10)

Country Link
US (1) US8735584B2 (es)
EP (1) EP2254889B1 (es)
JP (1) JP5529761B2 (es)
CN (1) CN101952287B (es)
AR (1) AR070540A1 (es)
AU (1) AU2009219376B2 (es)
CA (1) CA2712990C (es)
ES (1) ES2401550T3 (es)
IL (1) IL207415A (es)
WO (1) WO2009108670A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2367821B1 (en) * 2008-12-17 2015-09-16 Merck Patent GmbH C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
GB2486631A (en) * 2010-12-01 2012-06-27 Univ Sheffield Phenol/quinone boronic acids/esters and method of preparation thereof
MX352844B (es) 2011-02-28 2017-12-11 Calitor Sciences Llc Compuestos de quinolina sustituidos y metodos de uso.
RU2013144820A (ru) * 2011-03-08 2015-04-20 Басф Се Способ получения первичных аминов аминированием спиртов при гомогенном катализе
AU2012294917A1 (en) * 2011-08-10 2014-03-20 Merck Patent Gmbh Pyrido-pyrimidine derivatives
US8969388B1 (en) 2012-07-28 2015-03-03 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
US8975282B2 (en) 2012-07-28 2015-03-10 Sunshine Lake Pharma Co., Ltd. Substituted pyrazolone compounds and methods of use
EP2953933A1 (en) * 2013-02-07 2015-12-16 Merck Patent GmbH Substituted acetylene derivatives and their use as positive allosteric modulators of mglur4
US11548860B2 (en) * 2015-10-22 2023-01-10 Mangosuthu University Of Technology Pharmacophores, compounds and methods having application in the treatment of cancer through inhibition of CYP17A1 and CYP19A1
CA3056886A1 (en) * 2017-03-21 2018-09-27 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same
CN113453684B (zh) 2018-12-28 2024-05-14 德西费拉制药有限责任公司 用于治疗癌症的csf1r抑制剂
CN116462677A (zh) * 2022-01-20 2023-07-21 上海和誉生物医药科技有限公司 一种多稠环prmt5抑制剂及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SK285141B6 (sk) 1996-02-13 2006-07-07 Astrazeneca Uk Limited Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje
EP0885198B1 (en) 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
MXPA02011770A (es) 2000-05-31 2003-04-10 Astrazeneca Ab Derivados de indol con actividad de dano vascular.
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
JP4323802B2 (ja) 2000-12-01 2009-09-02 エムジーアイ・ジーピー・インコーポレーテッド 化合物およびその使用

Also Published As

Publication number Publication date
CN101952287A (zh) 2011-01-19
EP2254889A1 (en) 2010-12-01
ES2401550T3 (es) 2013-04-22
WO2009108670A1 (en) 2009-09-03
JP2011513322A (ja) 2011-04-28
AU2009219376A1 (en) 2009-09-03
IL207415A0 (en) 2010-12-30
JP5529761B2 (ja) 2014-06-25
CA2712990C (en) 2016-09-27
CA2712990A1 (en) 2009-09-03
US8735584B2 (en) 2014-05-27
CN101952287B (zh) 2013-11-27
AU2009219376B2 (en) 2014-09-25
EP2254889B1 (en) 2012-12-19
IL207415A (en) 2016-12-29
US20110053906A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
AR070540A1 (es) Derivados de 6-oxo-5, 6-dihidro-benzo[c][1, 8]naftiridina, un proceso para su preparacion, un kit que los incluye y su uso en la fabricacion de medicamentos para el tratamiento del cancer.
FI111633B (fi) Menetelmä farmakologisesti aktiivisten 7-deoksi-taksolianalogien valmistamiseksi
AR066543A1 (es) Derivados de piridazinona
PE20090060A1 (es) ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR
AR066892A1 (es) Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit
MX9203122A (es) Compuestos analogos de distamicina a y composiciones farmaceuticas que los contienen.
AR056979A1 (es) Derivados de dihidrobenzofuranos y usos de los mismos
AR068657A1 (es) Derivados de piperidina y piperazina
AR057214A1 (es) Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas.
MY140528A (en) Spiroketal derivatives and their use as therapeutic agents for diabetes
AR068658A1 (es) Derivados de tiazol
AR072860A1 (es) Derivados de 3-(3-pirimidin-2-il-bencil)-[1,2,4]triazolo[4,3-b]piridazina
AR063804A1 (es) Compuestos de azoniabiciclo[2.2.2]octano
AR055041A1 (es) Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
AR071208A1 (es) Derivados de piridazinona
EA200701035A1 (ru) Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения
SV2010003464A (es) Derivados de pirimida utiles para el tratamiento de condiciones inflamatorias o alergicas
EA200970582A1 (ru) ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5Н-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH
AR072192A1 (es) Derivados de tiazolil-piperidina
RU2011133128A (ru) Противоопухолевые соединения дигидропиран-2-она
AR058398A1 (es) Diazepinonas, procesos de obtencion , composiciones farmaceuticas y su uso como inhibidores de quinasas.
AR075122A1 (es) Derivados de piridazinona
AR071217A1 (es) Derivados bencimidazol
MY129329A (en) 6,7-DIHYDRO-5H-PYRAZOLO[1,2-a]PYRAZOL-1-ONES WHICH CONTROL INFLAMMATORY CYTOKINES
US4125547A (en) 12,13(E)-Didehydro-13,14-dihydro-9-deoxy-PGD1 compounds

Legal Events

Date Code Title Description
FG Grant, registration